Home/Pipeline/Novel Immunology Biologics

Novel Immunology Biologics

Ulcerative Colitis, Crohn's Disease

Phase 2Active

Key Facts

Indication

Ulcerative Colitis, Crohn's Disease

Phase

Phase 2

Status

Active

Company

Boehringer Ingelheim

About Boehringer Ingelheim

Boehringer Ingelheim is a major, privately-held German pharmaceutical powerhouse with a significant global footprint in human and animal health. Its strategy is built on deep research expertise across multiple therapeutic modalities, including immunology, cardiometabolic diseases, and oncology. The company maintains a robust pipeline and invests heavily in R&D, supported by a stable financial position due to its private ownership structure. Its key challenges include navigating intense therapeutic area competition and the inherent risks of late-stage clinical development.

View full company profile

Therapeutic Areas

Cardio-Renal-Metabolism Immunology Oncology Mental Health Animal Health

Other Ulcerative Colitis, Crohn's Disease Drugs

Drug	Company	Phase	Status
Filgotinib (JYSELECA)	Gilead	Approved (RA) / Phase 3	Active
Novel Immunology Candidate	Teva Pharmaceutical Industries	Phase 3	Active